menu
    • menu
    [{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||G-CSF receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ANX1502","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Velico Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Spray-Dried Plasma","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Velico Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Velico Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Velico Medical \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SCB-219M","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"SMAD-2\/SMAD3 pathway","graph1":"Hematology","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bond Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bond Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bond Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezagepras","moa":"GPR84","graph1":"Hematology","graph2":"Phase I","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Hematology","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR-4 receptor","graph1":"Hematology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zaltenibart","moa":"MASP-3","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SCB-219M","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EP-7041","moa":"Factor XIa","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Hematology","graph2":"Phase I","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL \/ Translational Sciences","highestDevelopmentStatusID":"6","companyTruncated":"CSL \/ Translational Sciences"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"STP122G","moa":"Factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"BioTrack Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"SRSD107","moa":"Factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirius Therapeutics \/ BioTrack Capital","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ BioTrack Capital"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sirius Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Sirius Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : BioTrack Capital

                            Deal Size : $50.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Sirius Raises $50M to Advance siRNA Therapies for Cardiometabolic Diseases

                            Details : The funds from this round will further advance clinical programs and expand pipeline including SRSD107, which is being evaluated for the treatment of thromboembolic disorders.

                            Product Name : SRSD107

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            May 09, 2025

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : BioTrack Capital

                            Deal Size : $50.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sirius Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Sirius Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sirius Shares Promising Phase 1 Data for Factor XI siRNA in Thromboembolic Disorders

                            Details : SRSD107 is a Factor XI inhibitor siRNA drug candidate, which is currently being evaluated for the treatment of thromboembolic disorders.

                            Product Name : SRSD107

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bond Biosciences

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Bond Biosciences

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBI-001

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bond Biosciences Advances BBI-001 for Iron Overload After FDA Meeting

                            Details : BBI-001 is a novel oral drug designed to inhibit iron absorption by forming a selective iron chelate in the digestive tract, currently evaluated for hereditary hemochromatosis.

                            Product Name : BBI-001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 01, 2024

                            Lead Product(s) : BBI-001

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sirnaomics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Sirnaomics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP122G

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sirnaomics Reports Positive Results for GalNAc-Based RNAi Therapeutic STP122G

                            Details : STP122G is a GalNAc-based RNAi therapeutic, SC formulation, targetting Factor XI. It is in early-stage development as an anticoagulant, utilizing company's proprietary GalAhead platform.

                            Product Name : STP122G

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            August 07, 2024

                            Lead Product(s) : STP122G

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cadrenal Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Cadrenal Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Abbott Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cadrenal and Abbott Collaborate on Novel Anticoagulant Tecarfarin for LVAD Patients

                            Details : The collaboration aims to advance the novel anticoagulant ATI-5923 (tecarfarin), designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices.

                            Product Name : ATI-5923

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 08, 2024

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Abbott Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Clover Biopharmaceuticals

                            China arrow
                            IFT FIRST
                            Not Confirmed

                            Clover Biopharmaceuticals

                            China arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SCB-219M

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopeni...

                            Details : SCB-219M is an innovative TPO-RA mimetic bispecific Fc-fusion protein produced from CHO cells. It is under phase 1 clinical development for the treatment of cancer patients with chemotherapy-induced thrombocytopenia.

                            Product Name : SCB-219M

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 28, 2023

                            Lead Product(s) : SCB-219M

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Annexon Biosciences

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Annexon Biosciences

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANX1502

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pat...

                            Details : ANX1502 is a classical complement pathway inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of patients with cold agglutinin disease.

                            Product Name : ANX1502

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 20, 2023

                            Lead Product(s) : ANX1502

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Velico Medical

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Velico Medical

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Spray-Dried Plasma

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Velico Medical Begins Clinical Trial on Spray Dried Plasma

                            Details : FrontlineODP(OnDemandPlasma) spray which is investigated in first in-human clinical trial Phase I safety trial for the prevention of trauma-induced coagulopathy.

                            Product Name : FrontlineODP

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            December 07, 2023

                            Lead Product(s) : Spray-Dried Plasma

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sirius Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Sirius Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA

                            Details : SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). it specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/an...

                            Product Name : SRSD107

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            September 11, 2023

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Bond Biosciences

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Bond Biosciences

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBI-001

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bond Biosciences Announces Positive Phase Ia/b Pharmacodynamic and Safety Data for BBI-001, a Novel, Non-Absor...

                            Details : BI-001 is a novel investigational new drug. It is a non-absorbed, oral therapeutic designed to rapidly form a strong and selective iron chelate in the digestive tract, thus inhibiting iron absorption in patients with symptomatic iron overload due to HH.

                            Product Name : BBI-001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 19, 2023

                            Lead Product(s) : BBI-001

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth